专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005123916A2 GLYCOSYLATION-DISRUPTED FACTOR VII VARIANTS 审中-公开
标题翻译：糖苷化破坏因子VII变种
公开(公告)号：WO2005123916A2
公开(公告)日：2005-12-29
申请号：PCT/EP2005/052834
申请日：2005-06-17
申请人： NOVO NORDISK HEALTH CARE AG , BOLT, Gert , STEENSTRUP, Thomas, Dock , KRISTENSEN, Claus
发明人： BOLT, Gert , STEENSTRUP, Thomas, Dock , KRISTENSEN, Claus
IPC分类号： C12N9/64
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to human coagulation Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions comprising Factor VII polypeptides, uses and methods of treatment; and any additional inventive features related thereto.
摘要翻译：本发明涉及人凝血因子VII多肽，以及编码此类多肽的多核苷酸构建体，载体和宿主细胞，其包含并表达多核苷酸，包含因子VII多肽的药物组合物，用途和治疗方法; 以及与其相关的任何其它发明特征。

2. 发明申请

WO2008135501A1 IMPROVEMENT OF FACTOR VIII POLYPEPTIDE TITERS IN CELL CULTURES 审中-公开
标题翻译：因子VIII多肽在细胞培养中的改进
公开(公告)号：WO2008135501A1
公开(公告)日：2008-11-13
申请号：PCT/EP2008/055349
申请日：2008-04-30
申请人： NOVO NORDISK A/S , JOHNSEN, Laust, Bruun , HILDEN, Ida , BOLT, Gert , STEENSTRUP, Thomas, Dock
发明人： JOHNSEN, Laust, Bruun , HILDEN, Ida , BOLT, Gert , STEENSTRUP, Thomas, Dock
IPC分类号： C07K14/755
CPC分类号： C07K14/755
摘要： The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
摘要翻译：本发明涉及生产因子VIII多肽的方法，该方法包括以下步骤：a）在表达所述因子VIII多肽的条件下培养表达因子VIII多肽的哺乳动物细胞，所述培养条件涉及细胞培养基包括C2结构域配体，和b）通过合适的方法从哺乳动物细胞分离表达的因子VIII多肽。

3. 发明申请

WO2009156511A2 N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE 审中-公开
标题翻译： N-糖化人体生长激素与延长循环半衰期
公开(公告)号：WO2009156511A2
公开(公告)日：2009-12-30
申请号：PCT/EP2009/058055
申请日：2009-06-26
申请人： NOVO NORDISK A/S , BOLT, Gert , KRISTENSEN, Claus , BOEL, Esper , LUNDGAARD, Thomas Veje
发明人： BOLT, Gert , KRISTENSEN, Claus , BOEL, Esper , LUNDGAARD, Thomas Veje
IPC分类号： C07K14/435
CPC分类号： C07K14/61 , A61K38/00 , C07K2319/91
摘要： The present invention relates to novel human growth hormone (h GH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The h GH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of h GH. The process of obtaining the hGH variants is also encompassed by the invention.
摘要翻译：本发明涉及具有一种或多种N-聚糖的新型人生长激素（h GH）变体。本发明的hGH变体包含氨基酸序列，其包含由野生型hGH中不存在的一种或多种突变产生的至少一种N-糖基化基序（N-X-S / T）。本发明的h GH变体具有延长的循环半衰期，因此可以有效地用作将受益于h GH水平升高的疾病状态的蛋白质治疗。获得hGH变体的方法也包括在本发明中。

4. 发明申请

WO2009130198A2 HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX 审中-公开
标题翻译：超高效人体凝血因子IX
公开(公告)号：WO2009130198A2
公开(公告)日：2009-10-29
申请号：PCT/EP2009/054707
申请日：2009-04-21
申请人： NOVO NORDISK A/S , BOLT, Gert , KRISTENSEN, Claus
发明人： BOLT, Gert , KRISTENSEN, Claus
IPC分类号： C07K14/435
CPC分类号： C12N9/644 , C12Y304/21022
摘要： The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
摘要翻译：本发明涉及高糖基化的人凝血因子IX多肽，制备所述多肽的方法，包含所述多肽的药物组合物和该化合物用于治疗由人凝血因子IX（特别是但不限于血友病）而减轻的疾病的用途。

5. 发明申请

WO2011101284A1 FACTOR VIII FUSION PROTEIN 审中-公开
标题翻译：因子VIII融合蛋白
公开(公告)号：WO2011101284A1
公开(公告)日：2011-08-25
申请号：PCT/EP2011/051959
申请日：2011-02-10
申请人： NOVO NORDISK A/S , BOLT, Gert , KJÆRGAARD, Kristian , NØRBY, Peder Lisby
发明人： BOLT, Gert , KJÆRGAARD, Kristian , NØRBY, Peder Lisby
IPC分类号： C07K14/755
CPC分类号： C07K14/755 , A61K38/00 , C07K14/70535 , C07K14/76 , C07K2319/00 , C07K2319/30 , C07K2319/31
摘要： The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
摘要翻译：本发明涉及改性凝血因子。特别地，本发明涉及与多肽融合的缀合因子VIII分子，例如。抗体结合蛋白或Fc结构域。

6. 发明申请

WO2006103298A2 BLOOD COAGULATION FVIII ANALOGUES 审中-公开
标题翻译：血液凝血FVIII类似物
公开(公告)号：WO2006103298A2
公开(公告)日：2006-10-05
申请号：PCT/EP2006/061275
申请日：2006-04-03
申请人： NOVO NORDISK A/S , ØSTERGAARD, Henrik , BOLT, Gert , DOCK STEENSTRUP, Thomas
发明人： ØSTERGAARD, Henrik , BOLT, Gert , DOCK STEENSTRUP, Thomas
IPC分类号： C07K14/755
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.
摘要翻译：本发明涉及FVIII类似物，FVIII类似物在活化至少约二分之一的天然FVIII之前在血流中具有循环时间，并且在注射至患者后一周内保留FVIII活性的至少约5％注射后达到初始活动峰值。要求保护的FVIII类似物包括通过引入至少一个N-糖基化位点或通过引入至少一个Cys残基在或在空间上靠近A2中的清除位点来定位破坏FVIII分子中的一个或多个清除位点域或其组合。插入的半胱氨酸残基可以通过与增加FVIII类似物的分子量的化学基团缀合来进一步修饰。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式